Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Indiana University Melvin and Bren Simon Cancer Center

535 Barnhill Drive, Indianapolis, IN 46202

At the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, more than 200 scientists conduct research in the areas of breast cancer; cancer prevention and control; experimental and developmental therapeutics; hematopoiesis, malignant hematology, and immunology; and tumor microenvironment and metastasis.

Each year, its physician-researchers lead more than 600 clinical trials for pediatric and adult cancers. IU Simon Cancer Center researchers are primarily faculty of the IU School of Medicine. They also include researchers from the IU School of Nursing, Purdue University, and the University of Notre Dame.

The IU Simon Cancer Center is Indiana’s only National Cancer Institute (NCI)-designated cancer center that provides patient care, and is one of only 68 in the nation. The NCI-designated Cancer Centers Program recognizes centers around the country that meet rigorous criteria for world-class, state-of-the-art programs in multidisciplinary cancer research.

The IU Simon Cancer Center also is a member of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.

Website: Indiana University Melvin and Bren Simon Cancer Center

Contact:
888-600-4822

Trials at this location:

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Open to Accrual
Read More

GI14-198

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients

Status: Open to Accrual
Read More

GI15-225

This is an open-label, multi-center pilot study designed to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 (Y90) radioembolization in subjects with poor prognosis (high-risk) hepatocellular carcinoma who are not eligible for liver transplant or surgical resection and who have well compensated liver function.

Status: Open to Accrual
Read More

GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Open to Accrual
Read More

GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Open to Accrual
Read More

LUN13-175

A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): HCRN LUN13-175

Status: Open to Accrual
Read More

LUN15-233

Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab.

Status: Open to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Open to Accrual
Read More